Subscribe

Prostate Cancer

With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
With Access to Care, Black Men in the United States Have Same Prostate Cancer Outcomes as White Men
By Phoebe Starr
Prostate Cancer
TON - September 2018, Vol 11, No 4
Chicago, IL—In the United States, black men are twice as likely to die from prostate cancer as white men, and they are often diagnosed at a younger age and at later stages of the disease. Read More ›
Practice-Changing Results with Abiraterone plus Prednisone in Metastatic Hormone-Naïve Prostate Cancer
By Meg Barbor, MPH
Prostate Cancer
TON - November 2017, Vol 10, No 6
For patients with metastatic hormone-naïve prostate cancer, practice-changing results from the LATITUDE clinical trial showed that the use of abiraterone plus low-dose prednisone in addition to androgen-deprivation therapy (ADT) delayed disease progression by an average of 18 months, and reduced the risk for death by 38%, when compared with ADT alone. Read More ›

Page 3 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.

We Value Your Feedback! Tell Us How You Consume Content

Your feedback will help us tailor our content to better meet your needs and preferences.

*First Name
*Last Name
*Email
*What's your favorite format for experiencing our content?